Is Unjha Formul. overvalued or undervalued?

As of 17 July 2025, the valuation grade for Unjha Formul. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, particularly when compared to its peers. Key ratios include a PE Ratio of 11.78, an EV to EBITDA of 11.14, and a PEG Ratio of 0.24, which suggests strong growth potential relative to its price.
In comparison to its peers, Unjha Formul.'s valuation metrics are significantly lower than those of Sun Pharma, which has a PE Ratio of 35.75, and Divi's Lab, with a PE Ratio of 82.21. Other peers like Cipla and Dr Reddy's Labs also show higher valuations, with PE Ratios of 22.71 and 18.67 respectively. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 14.10% compared to a -1.12% return for the index, reinforcing the attractiveness of its current valuation.